Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
Hannah Kuchler is a Global Pharmaceuticals Correspondent for the Financial Times. With a background in journalism and a focus on science and pharmaceuticals, Hannah's work covers a wide range of topics including Covid-19 vaccines, drug trials, gene-editing therapies, and the business of pharmaceutical companies. Her reporting has been featured in various publications and she is known for her expertise in the field.